Discussing PsA: Bimekizumab improves patient-reported outcomes and work productivity

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the longer-term impact of bimekizumab on patient-reported outcomes, health-related QoL, and work productivity in patients with active PsA who were bDMARD-naïve or had an inadequate response to TNFis for up to 1 year.